Abstract: The present invention provides the CP-BMP recombinant protein with technical advantages as an intracellular protein therapy for the treatment of bone defects caused by osteogenesis imperfecta, osteoporosis, fracture and osteoctomy in that it could resolve cell-/tissue-permeability and bio-transfer function.

Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.

Abstract: Provided herein are SIRP-gamma, SIRP-beta or SIRP-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.

Abstract: This invention provides for a fusion protein between an IL2??? Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2??? form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.

Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.

Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.

Abstract: Novel complexes of peptides from human collagen type II and types of MHC class II associated with rheumatoid arthritis are provided. There is also provided novel therapies and methods for diagnosis of rheumatoid arthritis.

Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.

Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.

Abstract: The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5.

Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes to the stem region, and methods of making and using both.

Abstract: The present disclosure provides fully human variant anti-AIP2 variant antibodies, and antigen binding proteins thereof, having improved characteristics compared to the wild type anti-AIP2 antibody E7 from which the variant clones are derived. The variant anti-AIP2 antibodies exhibit improved binding to AIP1 and AIP4 as determined in an in vitro quorum sensing reporter assay, have improved thermal stability, provided complete protection against infection with two different strains of Staphylococcus aureus MRSA in pre-treated mice, and can be manufactured at higher yields.

Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

Abstract: Compositions and methods reduce symptoms of human allergy to cats. The effectiveness of a molecule which specifically binds to Feline domesticus allergen number 1 (Fel D1) is enhanced by prolonging the time the immunoglobulin stays within the mouth of a cat to whom the anti-Fel D1 molecule is administered in a pet food. The compositions and methods use a powder that is a dried hydrogel encapsulating the anti-Fel D1 molecule, and the hydrogel is based on gelatin, collagen peptides, or gelatin and collagen peptides; and carrageenan. The methods of making the powder provide a high encapsulation efficacy, sustained release of the anti-Fel D1 molecule in the cat's mouth, and oral adhesion of the anti-Fel D1 molecule in the cat's mouth.

Abstract: Methods for making a combinatorial antibody library from human germline segments are provided. Also provided are libraries of nucleic acid molecules compiled from germline segments encoding VL chains and libraries of nucleic acid molecules encoding VH chains, and resulting antibody libraries. The libraries are provided as addressable libraries. Methods for screening antibody libraries against a target protein antigen, and the identified or selected antibodies are provided.

Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind Angiopoietin-like protein 8 (ANGPTL8), including human ANGPTL8, and methods of their use.

Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.

Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.

Abstract: The present invention relates to Anti-Mullerian Hormone (AMH) neutralizing antibodies and their use in the field of reproduction.

Abstract: Methods of modulating immune responses are provided, including contacting SLAT or IP3R1 with an agent that modulates binding of SLAT to IP3R1. Methods of modulating activation or differentiation of CD4+ T cells are also provided, including contacting SLAT or IP3R1 with an agent that modulates binding of SLAT to IP3R1. Peptides and fragments of an IP3R1 amino acid sequence that binds to a SLAT amino acid sequence, and peptides and fragments of a SLAT amino acid sequence that binds to am IP3R1 amino acid sequence, are further provided.

Abstract: Disclosed are a human programmed cell death 1 receptor (hPD-1) antibody, a method of preparing the same, and use thereof. The preparation method comprises screening by using a natural antibody library screening platform to obtain a new human programmed cell death 1 receptor antibody. The antibody obtained by the screening step can specifically identify human PD-1 molecules and is used to inhibit mutual interactions between PD-1/PD-L1 and PD-1/PD-L2, thereby improving a level of an immune response.

Abstract: The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.

Abstract: Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).

Abstract: The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.

Abstract: The invention provides fusion proteins comprising antigens of infectious disease agents and cancer cells linked to multiple-trimer forms of TNF SuperFamily (TNFSF) ligands. The TNFSFs serve as vaccine adjuvants for increasing the immune response to the antigens. In particular, a fusion polypeptide strand that self-assembles inside cells into a multiple-trimer form of CD40 ligand (CD40L, TNFSF5) is provided. Other similar fusion proteins are also disclosed. The fusion proteins can be delivered to a host as isolated proteins, as nucleic acids used directly in DNA vaccination or carried and expressed by a viral vector such as adenovirus. In addition to use as a vaccine to prevent or ameliorate disease caused by an infectious agent, compositions of the invention may be used for the treatment of ongoing infection or for cancer immunotherapy.

Abstract: The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets. The invention further provides compositions of said bispecific polypeptides, as well as methods and uses of the same.

Abstract: Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN?, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.

Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.

Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.

Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.

Abstract: The present invention relates to heterodimerically-tethered bispecific protein complexes (according to the general formula of A(A1)n-X:Y-B(B1)m and libraries/multiplexes thereof for use in research and therapy and in particular an in vitro/ex vivo method of detecting synergistic biological function of otherwise unknown pairs of targets. Such complexes may be used to capture soluble molecules secreted from a particular cell, in therapy, in research and for experimental purposes such as in assays to characterise patient populations by identifying cell populations relevant to a pathology or prognosis.

Abstract: A process for epoxidation of an unsaturated polymer involves mixing an unsaturated polymer and a peroxy acid in an absence of solvent to produce an epoxidized polymer. The process may require no solvent, require no catalyst, require no or little applied external heat input, require no applied cooling, require less epoxidation agent, be faster and/or result in more efficient conversion of the unsaturated polymer.

Abstract: A process to form an ethylene-based polymer comprising polymerizing a mixture comprising ethylene, in the presence of a free-radical initiator, and in a tubular reactor system comprising at least two ethylene-based feed streams, and a reactor configuration that comprises at least three reaction zones; and the inlet pressure of the first zone is <3200 Bar; and the ethylene conversion >28%, and an m value from 20 mole % to 70 mole %, where m=mol % of ethylene-based feed stream to the first zone, based on total moles of ethylene-based feed streams fed to the reactor configuration; and the ratio (Q) of a “MWDB of a broad polymer polymerized, to a “MWDN of a narrow polymer polymerized, is as follows: {(T)*(?2.3×log(m)+7)}?Q?{(T)*(?13.0×log(m)+29.8)}; at the same melt index; and “T” is the “chain transfer activity ratio” as described herein.

Abstract: The present invention relates to a supported hybrid catalyst system for ethylene slurry polymerization and a method for preparing ethylene polymer therewith. The supported hybrid catalyst system according to the present invention may exhibit high activity during ethylene slurry polymerization, and enables preparation of an ethylene polymer having a narrow molecular weight distribution but excellent processability.

Abstract: The present invention discloses methods for removing volatile components from an ethylene polymer effluent stream from a polymerization reactor, and related polyethylene recovery and volatile removal systems. In these methods and systems, the polymer solids temperature is increased significantly prior to introduction of the polymer solids into a purge column for the final stripping of volatile components from the polymer solids.

Abstract: A method for preparing cis-1,4-polydienes, the method comprising the steps of preparing a preformed, active lanthanide-based catalyst, aging the active lanthanide-based catalyst for more than 5 days to thereby formed an aged catalyst, and introducing the aged catalyst and conjugated diene monomer to be polymerized to thereby form an active polymerization mixture in which the conjugated diene monomer is polymerized to form a polydiene having a reactive chain end.

Abstract: The ethylene/1-hexene copolymer according to the present invention has excellent processability and mechanical properties, and thus can be applied to various fields such as food containers.

Abstract: Ionized radiation-absorbed, dose sensitive, highly flexible polymeric compositions are provided that exhibits multidirectional changes in refractive index. Also provided are methods of producing a precision multi-directional nanogradient of refractive index in a polymeric composition.

Abstract: The present invention relates to: a polymer composition; an article; a medical device; an article production method; and a cell cluster production method. The polymer composition contains a polymer having the following repeating units (A) and (B) and is one selected from the group consisting of a medical device composition, a cell adhesion inhibitor, and a silicone substrate treatment composition: (A) a hydrophilic repeating unit; and (B) a repeating unit which has a polyoxyalkylene group in a side chain whose terminal is constituted by an alkyl group having 5 to 30 carbon atoms, an alkanoyl group having 5 to 30 carbon atoms, or an aryl group having 6 to 30 carbon atoms.

Abstract: An object of the present invention is to provide a curable resin composition having low viscosity and being capable of forming a cured product which is excellent in the flexibility and the heat resistance. The present invention is a curable resin composition including: a (meth)acrylic group-containing vinyl-based polymer (A), a monomer (B) represented by the following Chemical formula (1), and a radical initiator (C).

Abstract: The present invention provides a modified polyolefin resin that can form a coating that exhibits excellent adhesion to a low-polarity base material, especially a poorly adherable polyolefin base material with no surface treatment even when being dried at low temperatures and has flexibility (bendability). Provided is a modified polyolefin resin that is a modified product of a polyolefin resin having a melting point (Tm) by a differential scanning calorimeter (DSC) of 60 to 165° C. with a modifier comprising the following (A): (A) a monomer mixture comprising Monomer Group (A-1) and Monomer Group (A-2) with a weight ratio of Monomer Group (A-1) to Monomer Group (A-2) ((A-1)/(A-2)) of 30/70 to 50/50.

Abstract: A silane-grafted polyolefin composition is disclosed and includes a desired reduced specific weight material. The composition finds application in a wide array of uses, and in particular automotive and uses such as windshield wipers, where this composition is used in place of conventional materials such as TPV and EPDM rubber formulations.

Abstract: The present application relates to brush amphiphilic block copolymers comprising at least one block which is hydrophilic and at least another block which is hydrophobic.

Abstract: The present invention relates to processes for the manufacture of aqueous polyurethane dispersions that can be used as adhesives or coatings, are solvent free and have low VOC emissions, and are environmentally friendly. Also encompassed are the dispersions as such, compositions containing them and their use as coatings and adhesives.

Abstract: Energetic nitrogen-rich monomers represented by the general Formula I: wherein each of X1 and X2 is independently NR or a covalent bond, R is H or C1-4 alkyl, each of T1 and T2 is independently a moiety selected from the group consisting of a triazole moiety, a tetrazole moiety and a guanidine moiety, at least one of T1 and T2 being substituted by at least one polymerizable group, are disclosed herein, as well as polymers based thereon, and uses of such polymers.

Abstract: A crystalline non-reinforced thermoplastic polyurethane composition having a high flexural modulus comprises 5% to 25% of a hydroxyl-functional polyol intermediate having a weight average molecular weight of 250 to 3000 and 75% to 95% hard segment comprising an unbranched, unsubstituted, linear chain diol and an aromatic isocyanate.

Abstract: The present invention relates to a thermosetting resin composition, and a prepreg and a printed circuit board using the same and, more particularly, to a thermosetting resin composition, and a prepreg and a printed circuit board using the same, wherein the thermosetting resin composition can be used for a printed circuit board which simultaneously has excellent low dielectric loss characteristics, good moisture absorption and heat resistance, low thermal expansion characteristics, and thermal stability.